SCHEMBL7498201

SCHEMBL7498201

ClC1Nc2ccccc2N1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.49
▸ ALOX12 P18054 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ HTT P42858 2/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ ATM Q13315 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ EHMT2 Q96KQ7 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ HDAC2 Q92769 3/20 0.40
▸ HDAC8 Q9BY41 3/20 0.40
▸ HDAC6 Q9UBN7 3/20 0.40
▸ ALDH2 P05091 1/20 0.38
▸ CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18535188 0.81 ALOX12 (0.55) LMNAALOX12MAPK1MEN1KMT2A
SCHEMBL5199567 0.81 LMNA (0.48) LMNAALOX12MAPK1MEN1KMT2A
SCHEMBL22726442 0.77 ALOX12 (0.48) LMNAALOX12MAPK1MEN1KMT2A
SCHEMBL18203599 0.72 EHMT2 (0.48) LMNAALOX12MAPK1MEN1KMT2A
SCHEMBL2956324 0.71 MEN1 (0.39) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL19019547 0.68 ESR1 (0.41) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL18844475 0.67 BRD4 (0.53) LMNAALOX12MAPK1EHMT2BRD4
SCHEMBL28626811 0.67 EHMT2 (0.40) LMNAALOX12MAPK1MEN1KMT2A
SCHEMBL29778116 0.66 HDAC2 (0.49) LMNAALOX12MAPK1EHMT2EPHX2
SCHEMBL31039937 0.66 POLB (0.49) MEN1KMT2AALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077967-B1 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-12-04 — — EP disclosed
US-6391897-B2 (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID, FOR EXAMPLE; INHIBIT PROTEIN-TYROSINE PHOSPHATASES (PTPASES) AMERICAN HOME PRODUCTS CORPORATION 2002-05-21 — — US disclosed
US-6369072-B2 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-04-09 — — US disclosed
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH 2001-12-20 — — US disclosed
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS 2001-11-15 — — US disclosed
US-6232322-B1 SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 — — US disclosed
EP-1077967-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 — — EP disclosed
WO-1999058518-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP LMNA 1435/4885ALOX12 1418/4885MAPK1 2116/4885
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP LMNA 1435/4885ALOX12 1418/4885MAPK1 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback